US court dismisses Cygnus lawsuit:
This article was originally published in Clinica
Executive Summary
The US Court of Appeals has upheld a 1995 decision to dismiss Cygnus' action against Alza (see Clinica No 589, p 12). Cygnus had sought a declaratory judgement of invalidity and/or unenforceability of Alza's patent relating to transdermal administration of fentanyl. The court dismissed Cygnus' case on jurisdictional grounds, rather than the merits of the argument says Gregory Lawless, Cygnus' CEO and president, says.